

FIG. 1

Reduction in HSV1 infectivity after treatment with various concentrations of apoE derived peptides




FIG. 2

Reduction in HSV2 infectivity after treatment with various concentrations of apoE derived peptides




FIG. 3

Reduction in HIV infectivity after treatment with various concentrations of apoE derived peptides




FIG. 4

Reduction in HSV1 infectivity after treatment with various concentrations of apoE derived peptides




FIG. 5

Reduction in HSV1 infectivity after treatment with various concentrations
of apoE derived peptides




FIG. 6

Reduction in HSV1 infectivity after treatment with various concentrations of apoE derived peptides




FIG. 7

Reduction in HSV1 infectivity after treatment with various concentrations of GIN peptides




FIG. 8

Reduction in HIV infectivity after treatment of NP2 glioma cells with various concentrations of GIN peptides




FIG. 9

AVERAGED DUTYCYCLES LW

LASERMat 2000

LaserMat 2000 mass spectrum

Sample: GIN 7



0.521254
6 shots

Fig. 10

CHANNEL A INJECT 04.02.04 10:00:48 STORED TO BIN # 1 :



HPIC analysis: Cln 7

DATA SAVED TO BIN # 1

04.02.04 10:00:48 CH= "A" PS= 1.

FILE	1.	METHOD	0.	RUN	1	INDEX	1	BIN	1
PEAK#		AREA%	RT		AREA	SC			
1		100.	17.25		116478	01			
TOTAL		100.			116478				